3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Ovarian Neoplasms
45
Breast Neoplasms
39
Triple Negative Breast Neoplasms
19
Prostatic Neoplasms
17
Neoplasms
13
Fallopian Tube Neoplasms
13
Endometrial Neoplasms
12
Recurrence
8
Pancreatic Neoplasms
8
Neoplasm Metastasis
8
Squamous Cell Carcinoma of Head and Neck
7
Small Cell Lung Carcinoma
7
Lung Neoplasms
6
Carcinoma, Ovarian Epithelial
6
Glioma
5
Glioblastoma
5
Carcinoma, Renal Cell
5
Uterine Cervical Neoplasms
4
Sarcoma
4
Carcinoma, Squamous Cell
4
Carcinoma, Non-Small-Cell Lung
4
Advanced Breast Cancer
4
Stomach Neoplasms
3
Solid Tumor
3
Melanoma
3
Head and Neck Neoplasms
3
Fanconi Anemia, Complementation Group D1
3
Uveal Melanoma
2
Uterine Neoplasms
2
Urinary Bladder Neoplasms
2
Interventions
Iodine-131
14
trametinib
9
dabrafenib
9
Thyroidectomy
9
Surgical Procedures, Operative
9
lenvatinib
8
Thyroxine
8
Magnetic Resonance Spectroscopy
8
pembrolizumab
7
Paclitaxel
7
anlotinib
6
Thyrotropin Alfa
6
selpercatinib
5
Sorafenib
5
Saline Solution
5
Radiofrequency Ablation
5
Everolimus
5
pazopanib
4
Vemurafenib
4
Sunitinib
4
Radiotherapy
4
Nivolumab
4
Fluorodeoxyglucose F18
4
Dexmedetomidine
4
Cyclophosphamide
4
Biopsy, Fine-Needle
4
Biopsy
4
Bevacizumab
4
apatinib
3
Triiodothyronine
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Thyroid Neoplasms
×
olaparib
×
Clear all
NCT05949424
2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4
Unknown
30 enrolled